6 Results for "

RGD sequence peptides

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "RGD sequence peptides" in MCE Product Catalog:

Cat. No.: HY-19307
CAS No.: 205678-31-5
SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with Ki values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. .
loading...
    loading...
Cat. No.: HY-P3732
CAS No.: 332179-76-7
Target:  

Integrin

Research Areas:  

Cancer

RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
loading...
    loading...
Cat. No.: HY-D2439
RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .
loading...
    loading...
Cat. No.: HY-P11428
CAS No.: 2425606-55-7
Research Areas:  

Others

DBCO-cyclo (RGDfK) is a clickable DBCO-modified cyclic RGD peptide, and also a DBCO derivative of cyclo (RGDfK) (HY-P0023). DBCO-cyclo (RGDfK) is synthesized via an amide coupling reaction between DBCO-NHS ester and cyclo (RGDfK). DBCO-cyclo (RGDfK) can react with azide groups through copper-free click chemistry (SPAAC) to immobilize RGD peptides onto biomaterials or hydrogels. The RGD sequence in DBCO-cyclo (RGDfK) is recognizable by cellular integrins and promotes cell adhesion. DBCO-cyclo (RGDfK) can be used in studies related to tissue engineering, 3D cell culture, and surface functionalization of biomaterials .
loading...
    loading...
Cat. No.: HY-157157
CAS No.: 2642327-44-2
Research Areas:  

Cancer

PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linked to RGD sequence peptide-modified chitosan (K-CRGDV), resulting in an enhanced oxidative stress-responsive nanoagent. K-CRGDV-PAD4-IN-3 can actively target tumors, inhibit PAD4 activity, block the formation of neutrophil extracellular traps (NETs), and improve the tumor immune microenvironment in response to the tumor microenvironment .
loading...
    loading...
Cat. No.: HY-126402
CAS No.: 120103-89-1
Target:  

Integrin

Research Areas:  

Cancer

Arg-Gly-Asp (RGD) is a synthetic peptide corresponding to the cell adhesion sequence for the integrins αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. It is a component of radioligands and peptidomimetics that have been used in the study of integrin expression and activity in vivo.
loading...
    loading...